Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS SEPTEMBER ISSUE PUBLISHED
  • SEPTEMBER 2020 Issue has been successfully launched on 1 September 2020.

Abstract

TRANSDERMAL APPROACH OF ANTIDIABETIC DRUG GLIBENCLAMIDE: A REVIEW

*Deepak Shrivastava

Indore Institute of Pharmacy (IIP) Indore Rau-Pithampur Road Indore (M.P.) India.

ABSTRACT

Transdermal drug delivery system (TDDS) provides a means to sustain drug release as well as reduce the intensity of action and thus reduce the side effects associated with its oral therapy. Transdermal drugs are self-contained, discrete dosage form . Diabetes Mellitus is a chronic metabolic disorder characterised by high blood glucose concentration hyperglycemia caused by insulin deficiency. often combine with insulin resistance. WHO report- WHO projects 346 million people worldwide has diabetes. In 2004, an estimated 3.4 million people died from consequences of high blood sugar. Glibenclamide is a potent oral sulfonylurea hypoglycemic agent. It has to passess some physiochemical properties which cause capable of facilitating the sorption of drug by the Stratum corneum. Glibenclamide (M.W. 494.004 g/mol) and negligible skin degradation. Therefore controlled released Transdermal prepration of Glibenclamide was prepare to give sustain effect as compared to conventional multiple oral dosing. It is currently available for treating hyperglycemia in Non insulin dependent Diabetes Mellitus (NIDDM-type 2).

Keywords: Transdermal drug delivery system, Diabetes Mellitus, Glibenclamide, Antidiabetic agent.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More